Formycon Adds FYB210 & FYB286 Biosimilars for Asthma & Hemophilia, Boosting Portfolio and Growth Potential
Formycon AG adds biosimilar candidates FYB210 (for Tezspire®) and FYB286 (for Hemlibra®) to boost asthma and hemophilia revenue.
2 minutes to read
